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INTRODUCTION
Squamous cell carcinoma of the head and neck (SCCHN) accoun-
ted for 3.5% of all the registered cancers in Korea during 2001
(1). SCCHN is believed to be induced by environmental carcino-
gens. Tobacco smoking and alcohol consumption are recognized
as major risk factors of SCCHN, yet only a small fraction of indi-
viduals exposed to tobacco or alcohol actually develop SCCHN.
(2). Therefore, the possibility of genetic susceptibility due to the
polymorphisms and phenotypic variations in the DNA repair en-
zymes or the metabolic enzymes that protect against the carcino-
gens in tobacco or alcohol have received much attention in atte-
mpts to determine the causes of SCCHN (3-6). The higher frequen-
cy of SCCHN in the first-degree relatives of SCCHN patients (7)
and the early onset SCCHN in a subgroup of patients (8) lends su-
pport for such genetic susceptibility. 
Accumulating evidence has shown that genetic differences in
the DNA repair capacity and that are the result of genetic poly-
morphisms influence the risk of environmental carcinogenesis
(9, 10). The importance of DNA repair for modulating the can-
cer risk of humans originated from the observation that individ-
uals with the skin cancer-susceptible human disease xeroderma
pigmentosum (XP) have defective nucleotide excision repair
(NER). XP is a genetically complex disease that involves eight
different complementation groups (A-G) (11).
XPD protein is one of nine subunits that compose transcription
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participates in NER and transcription initiation. The role of TFIIH
in NER is to open up the damaged DNA to permit damage-spe-
cific nucleases to cleave both sides of the damage site. XPD pro-
tein has single strand DNA-dependent ATPase and 5’-3’ DNA
helicase activities and this protein is thought to participate in
DNA unwinding during NER. Mutations in the XPD gene can
give rise to repair and transcription defects (12).  
In addition to these point mutations, variations in the XPD se-
quence are found in the general population. These variations are
called single nucleotide polymorphisms (SNPs) with a highly vari-
able frequency above 1%. To date, 17 polymorphisms in the XPD
gene have been identified, and it is thought that certain XPD
polymorphisms may be associated with the susceptibility to de-
veloping cancer (13). 
Polymorphisms in the XPD gene have been studied in rela-
tion to the risk for head and neck cancer or lung cancer. Sturgis
et al. (14, 15) reported that the XPD +35931A>C and +23591-
G>A SNPs are associated with a slightly increased risk of head
and neck cancer, although this was not statistically significant.
In a study on larynx, oral cavity and lung cancer, Buch et al.
(16) reported that XPD +23591G>A and XPD +35931A>C
SNPs are associated with a statistically significant increased risk
of SCCHN; however, in another study the variant genotype of
XPD +35931A>C showed no association with the risk of head
and neck cancer (17). Similar contradictory results have been
reported by studies on lung cancer (18-22).
No genetic study of XPD polymorphism in SCCHN has been
performed in a sample of the Korean population. In this study, we
investigated the frequencies of XPD SNPs in the SCCHN patients
and controls in a sample of the Korean population and we eval-
uated the estimated risk of SCCHN. 
MATERIALS AND METHODS
Study population
This case-control study was performed at the Department of
Otolaryngology-Head and Neck Surgery, Hanyang University
Hospital, Seoul, Korea from 1997 to 2004. The patient group con-
tained 290 cases with pathologically verified SCCHN; there were
148 cases of larynx cancer, 56 cases of oral cancer, 42 cases of oro-
pharynx cancer, 40 cases hypopharyx cancer and four cases of
cancer at other sites. The control group consisted of 358 patients
with chronic otitis media, chronic sinusitis or chronic tonsillitis,
and they had no history of previous malignant disease or genetic
disease. The patient group contained 252 males and 38 females
with a mean age of 62.6 yr (range, 28 to 90 yr), and the control
group contained 339 males and 19 females with a mean age of
38.8 yr (range, 21 to76 yr). All the participants provided us their
written informed consent. The study protocol was approved by
The Institutional Review Board of Hanyang University Hospital.
Peripheral blood specimens were taken from all the participants
and the samples were stored at -80℃ for DNA isolation. All
the participants completed a questionnaire on personal infor-
mation and lifestyle, including their smoking and drinking his-
tory. All the participants were ethnic Koreans.
Genotyping 
We extracted the DNA from the peripheral blood using the Wi-
zard
TM Genomic DNA purification kit (Promega, Madison, WI,
USA). 
Two SNPs of XPD, +23591G>A and +35931A>C, were ana-
lyzed using the single base extension (SBE) technique. Polymerase
chain reaction (PCR) using a GeneAmp PCR System 9700 ther-
mal cycler (Applied Biosystems, Foster City, CA, USA) was per-
formed on the samples, and the samples contained 1.25 pM of
each primer, 5 ng of genomic DNA, 250 mM of the dNTPs and
0.15U Taq DNA polymerase. The primers used in this study are
listed in Table 1. The primer extension reaction was performed
using the SNaPshot ddNTP primer extension kit (Applied Bio-
systems). One unit of shrimp alkaline phosphatase (Amersham
Life Science, Cleveland, OH, USA) was added to the reaction
mixture to clean up the primer extension reaction products, and
the mixture was incubated at 37℃ for one hour, followed by 15
min at 72℃ for enzyme inactivation. The amplified material and
Genescan 120 Liz size-standard solution (Applied Biosystems)
were added to Hi-Di formamide (Applied Biosystems) and this
was all reacted at 95℃ for five minutes, and then it was incu-
bated on ice for five minutes. Electrophoresis was performed
on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems)
and the genes were analyzed using ABI Prism GeneScan and
Genotyper software.
Statistical analysis
Statistical analysis of the XPD polymorphism frequencies between
the SCCHN and normal control groups was performed using
the chi square test. Odds ratios (OR), adjusted for age and gen-
der, and the 95% confidence intervals (95% CI) of a genetic
polymorphism and its associations were obtained using a logis-
tic regression model. All the statistical data was obtained using
SPSS ver. 15.0 (SPSS Inc., Chicago, IL, USA).
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Locus Primer (5’-3’)
Table 1. Sequences of the primers used for XPD single nucleotide
polymorphism genotyping by the single-base extension method
XPD Forward CCTGTCTGACTTGTCCCCAG
23591G>A Reverse CCACTTCACGTACTCCAGCA
Extension CCTGGCCAACCCCGTGCTGCCC
XPD Forward CAGGAACCGTTTATGGCCC
+35931A>C Reverse TCTCTGCAGGAGGATCAGCTG
Extension CAGAGCTGCTGAGCAATCTGCTCTAT-    
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RESULTS
The allele and genotype frequencies are summarized in Tables 2
and 3. For the XPD +23591G>A SNP, genotyping was available
in 606 of 648 subjects and the frequency of the variant allele A
was 5.1%. The genotype distributions of XPD +23591 GG, GA,
and AA were 89.0%, 11.0%, and 0% in the patient group and
90.4%, 8.8%, and 0.8% in the control group, respectively. The
odds ratio and 95% confidence interval of the genotype GA in
reference to GG was 1.94 (0.92 to 4.08). For the XPD +35931
A>C SNP, genotyping was available in 615 of 648 subjects and
the frequency of the variant allele C was 6.9%. The genotype dis-
tributions of XPD +35931 AA, AC, and CC were 86.9%, 12.0%,
and 1.1% in the patient group and 85.6%, 13.8%, and 0.6% in
the control group, respectively. The odds ratios and 95% confi-
dence intervals of the genotypes AC and CC in reference to AA
were 0.98 (0.51 to 1.88) and 2.68 (0.71 to 10.10), respectively. 
The risk estimates of SCCHN in the subgroups according to the
smoking and alcohol consumption status are summarized in Table
4. The patient and control groups were classified as non-smokers,
light smokers or heavy smokers. The light smoker group was de-
fined as having a smoking history of <20 pack-year (number of
packs smoked/day multiplied by the number of years of smoking)
and the heavy smoker group was defined as having ≥20 pack-
year. There were no statistically significant differences in the risk
of SCCHN according to the smoking status. 
The patient and control groups were also classified according
to alcohol consumption into non-drinkers, social drinkers or heavy
drinker. The social drinker group was defined as those who con-
Loci   Genotype  Frequency  Heterozygosity
Table 2. Allele frequencies of the XPD single nucleotide polymor-
phisms in the Korean head and neck squamous cell carcinoma
patients and the controls
Loci  Genotype Case (%) Control (%) ORadj (95% CI)
Table 3. Genotype frequencies of the XPD single nucleotide poly-
morphisms in the Korean head and neck squamous cell carcino-
ma patients and the controls
+23591G>A GG A AN
544 59 3 606 0.051 0.097
+35931A>C AA C CN
530 80 5 615 0.069 0.130
+23591G>A GG 235 (89.0) 309 (90.4) 1.0
GA 29 (11.0) 30 (8.8) 1.94 (0.92-4.08)
AA 0 ( 3 (0.8)
+35931A>C AA 232 (86.9) 298 (85.6) 1.0
AC 32 (12.0) 48 (13.8) 0.98 (0.51-1.88)
CC 3 (1.1) 2 (0.6) 2.68 (0.71-10.10)
ORadj: Odds ratio adjusted for age and gender; CI: confidence interval.
XPD 23591G>A (codon 312) XPD 35931A>C (codon 751)
Case (%) Control (%)  ORadj (95% CI)           Case (%)  Control (%)   ORadj (95% CI)
Table 4. Genotype frequencies of the XPD single nucleotide polymorphisms and risk estimates according to the smoking and alcohol drink-
ing statuses
*<20 pack-year; 
� ≥20 pack-year; 
� alcohol consumption <2 times per week; 
�alcohol consumption ≥2 times per week.
ORadj: odds ratio adjusted for age and gender; CI: confidence interval.
Smoking
Non-smoker GG 38 (14.4) 2 (0.6) 1 AA 36 (13.5) 1 (0.3) 1
GA 3 (1.5) 0 AC 5 (1.9) 1 (0.3) 7.2 (0.39-34.22)
AA 0 2 (0.6) CC 0 0
Light smoker* GG 27 (10.2) 152 (44.4) 1 AA 29 (10.9) 148 (42.5) 1
GA 7 (2.7) 13 (3.8) 2.4 (0.78-7.35) AC 6 (2.2) 21 (6.0) 1.27 (0.40-4.08)
AA 0 2 (0.6) CC 0 2 (0.6)
Heavy smoker
� GG 170 (64.4) 155 (45.3) 1 AA 167 (62.5) 149 (42.8) 1
GA 18 (6.8) 17 (5.0) 0.94 (0.47-7.35) AC 21 (7.9) 26 (7.5) 0.73 (0.39-1.36)
AA 0 1 (0.3) CC 3 (1.1) 0
Drinking
Non-drinker GG 64 (24.3) 71 (20.8) 1.0 AA 59 (22.1) 67 (19.3) 1.0
GA 7 (2.7) 6 (1.7) 1.51 (0.46-5.00) AC 10 (3.7) 13 (3.7) 1.16 (0.43-3.13)
AA 0 3 (0.9) CC 0 1 (0.3)
Social drinker
� GG 69 (26.1) 129 (37.7) 1.0 AA 72 (27.0) 124 (35.6) 1.0
GA 9 (3.4) 12 (3.5) 1.10 (0.41-0.29) AC 8 (3.0) 19 (5.5) 0.58 (0.22-1.53)
AA 0 0 CC 1 (0.4) 1 (0.3) 1.74 (0.11-28..57)
Heavy drinker
� GG 102 (38.6) 109 (31.9) 1.0 AA 101 (37.8) 107 (30.7) 1.0
GA 13 (4.9) 12 (3.5) 1.07 (0.46-2.49) AC 14 (5.2) 16 (4.6) 0.86 (0.39-1.88)
AA 0 0 CC 2 (0.8) 0Ji YB et al.: XPD Polymorphisms in Head and Neck Cancer 45
sumed alcohol <2 times per week and the heavy drinker group
was defined as those who consumed alcohol ≥2 times per week.
There were no statistically significant differences in the risk of
SCCHN according to the alcohol drinking status. 
We also analyzed the XPD polymorphisms and the risk of SC-
CHN according to the tumor subsite (oral cavity, larynx, hypo-
pharynx and oropharynx). There were no statistically significant
differences according to the tumor subsite. 
The most common haplotype (abbreviated as ht1) for XPD
+23591G>A, +35931A>C was analyzed and the haplotype
distribution is summarized in Table 5. There were no significant
differences in the distribution of the XPD haplotype between
the SCCHN and normal control groups.
DISCUSSION
DNA repair systems play an important role not only in ensuring
cellular survival, but also in preventing the development of can-
cer. At least four DNA repair pathways, including nucleotide ex-
cision repair, base excision repair, mismatch repair and double
strand DNA break repair are involved in the repair of specific
types of DNA damage. Aberrant DNA repair is associated with
the development of several cancer types (13).
The NER pathway is the most versatile and ubiquitous mech-
anism for DNA repair and it is primarily involved in protection
against the genotoxic damage induced by UV-irradiation or che-
mical carcinogens. In NER, the damaged part of a DNA strand
is excised and then the gap is filled by repair replication using
the complementary strand as a template. This “cut and patch”
mode consists of five major steps: 1) recognition of the damaged
DNA site, 2) incision of the damaged DNA strand on both sides
of the defect, 3) removal of the damaged strand containing the
lesion, 4) DNA replication to replace the excised region using
the complementary strand as a template and 5) ligation to join
the 3’ end of the repair patch to the contiguous parental DNA
strand (13, 23). Defects in the NER pathway are responsible for
several human syndromes, including Cockayne syndrome, tri-
chothiodystrophy and xeroderma pigmentosum, which are all
characterized by defective repair of UV-damaged DNA and an
increased risk of skin cancer (11).
Many of the studies on XPD SNPs have focused on +23591G
>A, which is located at codon 312 of exon 10 and Asn is substi-
tuted for Asp, and +35931A>C, which is located at codon 751 of
exon 2 and Gln is substituted for Lys. Several authors have sug-
gested that these amino acid substitutions might alter XPD activ-
ity and so contribute to cancer development (13, 24).
This is the first study that has examined the relationship bet-
ween XPD SNPs and the risk of SCCHN in a Korean cohort.
We analyzed the XPD +23591G>A and +35931A>C SNPs in
SCCHN patients and a control group. Overall, we could not
find statistically significant differences in the XPD polymor-
phisms +23591G>A and +35931A>C between the SCCHN
patients and the controls, although the XPD +23591 GA geno-
type showed a slightly increased risk of SCCHN (OR, 1.94; 95%
CI, 0.92 to 4.08). We believe that further studies with larger
numbers of subjects are warranted to confirm the role of these
SNPs in SCCHN. 
Several studies have examined the significance of XPD poly-
morphisms in head and neck cancer or lung cancer. Sturgis et al.
reported that the XPD +35931 CC genotype is associated with
a borderline increased risk for SCCHN (OR, 1.55; 95% CI, 0.96
to 2.52) (14). Furthermore, the XPD +23591 GA/AA genotype
was associated with a slightly increased risk of SCCHN (OR, 1.28;
95% CI, 0.93 to 1.76), and subsequent studies showed that the
risk was higher in combination with the ERCC1 8092 CC geno-
type (OR, 1.78; 95% CI, 0.99 to 3.17) (15), but they could not de-
monstrate statistical significance. In a study on larynx, oral cavi-
ty and lung cancer, Buch et al. (16) demonstrated that both the
XPD +23591 GA/AA and XPD +35931 AC/CC genotypes were
associated with a significantly increased risk of cancer (OR, 1.3,
95% CI, 1.0 to 1.8; OR, 1.5, 95% CI, 1.3 to 2.0, respectively).
Furthermore, they found that the XPD +35931 AC/CC genotype
in combination with the CCND1 870 GA/AA genotype marked-
ly increased the risk of cancer (OR, 7.09; 95% CI, 4.03 to 12.5).
In contrast, Huang et al. (17) reported that the XPD +39591A>
C SNP was not associated with an increased risk of head and neck
cancer. 
There is similar controversy concerning studies on XPD SNPs
and lung cancer. Spitz et al. (18) demonstrated that the combi-
nation of the XPD +23591 AA and +35931 CC genotypes show-
ed an increased risk of lung cancer (OR, 1.84; 95% CI, 1.11 to
3.04), although each variant genotype of XPD +23591G>A and
+35931A>C was not associated with increased cancer risk by
itself. Two studies on Chinese lung cancer patients also reported
that the XPD +23591 AA and +35931 CC genotype was asso-
ciated with an increased risk of lung cancer (19, 20). However,
several other authors have reported different results. Park et al.
(21) reported that the distribution of the XPD +35931 AA/AC/
CC genotype was not significantly different between the patients
and controls, and they concluded that the XPD +35931A>C SNP
was not associated with the risk of lung cancer in Koreans. Ryu
et al. (22) also reported that the XPD +23591G>A and +3593-
1A>C SNPs had no association with the chemotherapy response
Loci  Genotype  Case (%)  Control (%)  ORadj (95% CI)
Table 5. Analysis of the haplotype of the XPD gene in the Korean
head and neck squamous cell carcinoma patients and the controls
ORadj: odds ratio adjusted for age and gender; CI: confidence interval.
ht1 ht1/ht1 216 (83.4) 285 (83.8) 1
ht1/- 40 (15.4) 51 (15.0) 1.32 (0.72-2.42) 
-/- 3 (1.2) 4 (1.2) 1.35 (0.51-3.59) 
Total 259 (100) 340 (100)and prognosis of Korean lung cancer patients. 
In the present study using a Korean cohort, the frequency of
the variant A allele of the XPD +23591G>A SNP was 5.1%, and
the frequency of the GA and AA genotypes was 9.6% and 0.5%,
respectively. The frequency of the variant C allele of the XPD
+35931A>C SNP was 6.9%, and the frequency of the AC and
CC genotypes was 13.0% and 0.8%, respectively. The variant
allele frequencies of the XPD +23591G>A SNP and the +35931
A>C SNP in this study were markedly lower than those of pre-
vious studies in western countries, which reported the frequency
of the variant A allele of XPD +23591G>A to be 33-38% and
frequencies of the GA and AA genotypes to be 37-47% and 10-
19%, respectively. They also reported the frequency of the vari-
ant C allele of XPD +35931A>C to be 36-41%, and frequencies
of the AC and CC genotypes to be 37-52% and 10-17%, respe-
ctively (25-27). However, our results are similar to several stu-
dies conducted in East Asian populations. In one study on lung
cancer in a Chinese sample, the frequency of the A allele in XPD
+23591G>A was 6.9% and the frequencies of the GA and AA
genotypes were 12.6% and 0.6%, respectively; the frequency of
the C allele of XPD +35931A>C was 8.8% and the frequencies
of the AC and CC genotype were 15.7% and 1.0%, respective-
ly (19). Another study of a Japanese cohort reported the frequen-
cy of the C allele of XPD +35931A>C to be 5.2% and the fre-
quencies of the AC and CC genotypes to be 8.8% and 0.8% (28).
To date, there are two reports on XPD polymorphisms in Korean
lung cancer patients. One study showed that the frequency of the
C allele of XPD +35931A>C was 6.7% and the frequency of the
AC and CC genotypes was 11.6% and 0.4%, respectively (21).
In the other study, the frequency of the A allele in XPD +23591
G>A was 3.7%, and the frequency of the GA and AA genotypes
was 7.4% and 0%, respectively; the frequency of the C allele of
XPD +35931A>C was 5.6% and the frequency of the AC and CC
genotypes was 11.1% and 0%, respectively (22). We suggest that
a low variant allele frequency of XPD SNPs in the Korean pop-
ulation might explain the difference between our results and
those derived from Caucasian samples.
The XPD +23591G>A and +35931A>C SNPs were not asso-
ciated with the risk of SCCHN in a Korean sample. We observed
markedly lower frequencies of the variant alleles XPD +23591
G>A and +35931A>C SNPs in this Korean sample, as compared
with those of Caucasians. The low frequency of variant alleles
might explain our failure to find a statistically significant associa-
tion between the XPD SNPs and the risk of SCCHN. Further stu-
dies with larger numbers of cases are necessary to clarify the
exact relationship between XPD SNPs and the risk of SCCHN.
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